Icon

ZINECARD (nda020212)- (EQ 250MG BASE/VIAL,EQ 500MG BASE/VIAL)

DEXRAZOXANE HYDROCHLORIDE PFIZER
EQ 250MG BASE/VIAL,EQ 500MG BASE/VIAL
Yes No
2010-Sep-07 Expired
None None
None No
ZINECARD is a cytoprotective agent indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control.
3 0 3
Total Other Developers 1
Drugs with Suitability No
EQ 250MG BASE/VIAL ** ** - - -
EQ 500MG BASE/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
No 3
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** ********** **** ********* *********** ************ **, **********, ***** ****** *****, ******* (***) ***
****** ***** ****** ***** ****** ******* *** *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***
****** ***** ****** ***** ****** ******* *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***
****** ***** ***** ****** ******* *** *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***
****** ***** ***** ****** ******* *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.